HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
Status:
Completed
Trial end date:
2020-06-05
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients
with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
National Cancer Institute (NCI) Peloton Therapeutics, Inc.